Otavio Frederico De Toledo

Otavio Frederico De Toledo

Auto-generated profile, based on publicly available information

Otavio Frederico De Toledo

Lyerly Neurosurgery, Baptist Medical Center Downtown, Jacksonville, Florida, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2024 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
PDF file
YKYasha Kayan
Yasha Kayan
JAJosser E Delgado Almandoz
Josser E Delgado Almandoz
ACAlexander Copelan
Alexander Copelan
CMCharles C Matouk, MD
Charles C Matouk, MD
MCM Imran Chaudry
M Imran Chaudry
APAlexandra R. Paul
Alexandra R. Paul
Background Stent development has focused recently on low-profile, self-expandable stents compatible with 0.0165 inch microcatheters. The LVIS EVO is the second-generation version of the Low-Profile Visualized Intraluminal Support (LVIS) with improved visibility and resheathability. The LVIS EVO underwent a limited premarket release (PMR) in December 2023. This study aims to report the early safety and feasibility experience with the LVIS EVO stent for the treatment of intracranial aneurysms in the United States (US). Methods This was a multicenter, retrospective, observational study evaluating patients who underwent treatment of an intracranial aneurysm with an LVIS EVO stent after the limited PMR. All physicians who had placed an LVIS EVO stent were asked to input their cases after institutional review board approval was obtained. The data were then sent to a single center for analysis. Any patient aged 18 years or older who underwent treatment of an intracranial aneurysm with a LVIS EVO stent in the US was included from the initial PMR in December 2023 until April 2024. Patient age (or ≤90 years old), sex, preoperative modified Rankin Scale (mRS), aneurysm location, aneurysm measurements, and information about preoperative antiplatelet management were all collected. Data on periprocedural complications, 30-day mortality, discharge mRS, and length of stay were also collected. Results Some 53 patients with 55 aneurysms underwent treatment with the LVIS EVO stent at 15 institutions. All aneurysms were unruptured. The most common location was the anterior communicating artery (35%) followed by the middle cerebral artery bifurcation (31%). All patients were on dual antiplatelet therapy. The average aneurysm size was 5.2 mm with a neck size of 3.7 mm. The smallest distal parent vessel size was 1.2 mm and 36% of stents were deployed in distal parent vessels <2 mm. All (100%) cases had successful deployment and the stent was repositioned in 10% of cases. A single stent was utilized in 91% of cases. Coils were placed in 48 cases (87.2%) and a microcatheter was jailed in 98% of those cases. Immediate Raymond Roy (RR) Class I occlusion was obtained in 33%, Class II in 22%, Class IIIa in 37%, and Class IIIb in 8% of cases. There were no delayed thromboembolic or hemorrhagic complications. Conclusions The LVIS EVO is a braided, self-expanding, retrievable stent with enhanced visibility and smaller cell size. The drawn filled tube (DFT) technology results in improved visibility of the stent, allowing for more controlled stent positioning and visualization of vessel wall apposition. All cases in our series had complete neck coverage and good wall apposition. There were no thromboembolic or hemorrhagic complications.

10 May 2024 in World Neurosurgery
Verified
Journal Article
Closed access
OTOtavio F. De Toledo
Otavio F. De Toledo
SGSalvador F. Gutierrez-Aguirre
Salvador F. Gutierrez-Aguirre
MLMontserrat Lara-Velazquez
Montserrat Lara-Velazquez
AQAdnan I. Qureshi
Adnan I. Qureshi
WCWendy Camp
Wendy Camp
RHRicardo Hanel
Ricardo Hanel

1 October 2024 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
PDF file
FRFernanda Rodriguez-Erazú
Fernanda Rodriguez-Erazú
GCGustavo M Cortez
Gustavo M Cortez
DLDemetrius K Lopes
Demetrius K Lopes
SGSalvador F. Gutierrez-Aguirre
Salvador F. Gutierrez-Aguirre
OTOtavio Frederico De Toledo
Otavio Frederico De Toledo
RHRicardo Hanel
Ricardo Hanel
Background The pipeline embolization device (PED) has been increasingly used to treat brain aneurysms; however, concerns have been raised about braid stability with newer drawn filled tubing technology devices. Objective To evaluate braid stability of PED early generations using data from the PREMIER trial. Methods All consecutive intracranial aneurysms treated with PED (Classic and Flex) within the PREMIER trial were reviewed for braid stability (fish mouthing, foreshortening, braid bump, braid collapsing). Immediate postprocedure cone-beam CT and angiography were compared with 1- and 2- years' follow-up. Analyses included safety, measured with the modified Rankin Scale (mRS) score, including +1 mRS point and a good clinical outcome (mRS score 0–2), vessel stenosis ≥50%, effectiveness measured with Raymond-Roy Scale, and re-treatment rates. Results 133/141 aneurysms had a complete dataset. 8/133 (6%) aneurysms showed braid deformations. Inter-reader agreement was excellent (κ=0.83). Braid deformations were statistically significantly associated with in-stent vessel stenosis >50% (P=0.029), without impact on effectiveness or safety. Fish mouthing was found in 1/133 (0.75%) at 1 year, causing >50% vessel stenosis. Foreshortening occurred in 6/133 (4.5%), and braid bump in 1/133 (0.75%) associated with severe in-stent stenosis. Four other cases (3.0%) of asymptomatic in-stent stenosis due to neointimal hyperplasia were seen without braid changes. No new braid stability deformations were found at the 2-year follow-up. Conclusion Our study demonstrates excellent braid stability among patients treated with the PED Classic and Flex in the PREMIER trial. Within the uncommon braid changes observed, none affected the PED safety or efficacy. Trial registration number NCT02186561.

2 June 2025 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
AAAmin Aghaebrahim
Amin Aghaebrahim
OTOtavio F De Toledo
Otavio F De Toledo
FEFernanda Erazú
Fernanda Erazú
SGSalvador F. Gutierrez-Aguirre
Salvador F. Gutierrez-Aguirre
BJbrian jankowitz
brian jankowitz
RHRicardo Hanel
Ricardo Hanel
Background and objectives: Large-bore aspiration catheters have demonstrated better recanalization times and higher first-pass effects in large vessel occlusions. However, vessel tortuosity and branching vessels can hinder navigability, potentially increasing the ‘ledge effect’, procedural times, and the risk of vessel injury. Recently, a newly designed delivery catheter (Carrier Delivery Catheter (CDC), Balt, France) has been introduced to the US market. This paper aims to report our combined experience with this catheter in a real-life clinical setting. Methods: This is a retrospective, multicenter study based on a prospectively maintained database of patients with ischemic stroke who underwent mechanical thrombectomy between February 2024 and January 2025. All consecutive patients who underwent mechanical thrombectomy in which a CDC was used were included. Results: A total of 43 patients from three centers in the USA were included. The mean age was 69.74 years, and most of the patients were male (60.5%). The CDC delivered the aspiration catheter to the clot in all cases. The mean National Institutes of Health Stroke Scale (NIHSS) score was 18, and the mean time between puncture to clot access was 18.14 min. No vessel dissection or perforation was reported, and 4.6% of symptomatic hemorrhagic complications were reported. None of the complications were adjudicated to be directly related to the use of the Carrier. Conclusion: Our case series shows that the CDC is a useful and reliable tool as a delivery catheter for treating vessel occlusions in both the anterior and posterior circulation. This study serves as proof of concept and may provide a foundation for future prospective analyses of this innovative delivery system.

28 June 2024 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
LBLeonardo de Barros Oliveira Brenner
Leonardo de Barros Oliveira Brenner
SPSilvio Porto
Silvio Porto
FAFilipi Fim Andreão
Filipi Fim Andreão
MFMarcio Yuri Ferreira
Marcio Yuri Ferreira
JBJhon E. Bocanegra-Becerra
Jhon E. Bocanegra-Becerra
EFEberval G. Figueiredo
Eberval G. Figueiredo

8 February 2024 in Operative Neurosurgery
Verified
Journal Article
Closed access
OTOtavio F. De Toledo
Otavio F. De Toledo
SGSalvador F. Gutierrez-Aguirre
Salvador F. Gutierrez-Aguirre
VBVictor H. C. Benalia
Victor H. C. Benalia
MLMontserrat Lara-Velazquez
Montserrat Lara-Velazquez
AAAmin Aghaebrahim
Amin Aghaebrahim
RHRicardo Hanel
Ricardo Hanel
Y/stent, and transcervical carotid revascularization, certain patients are not ideal candidates for any of these modalities. Novel technical advances such as intravascular lithotripsy (Shockwave Medical Inc.) have emerged as a potential treatment modality to treat patients with severely calcified plaques, a well-described limitation for carotid stent expansion and apposition.2-4 The safety and efficacy of intravascular lithotripsy have been demonstrated through select case series and coronary artery disease I‐II‐III studies, culminating in its Food and Drug Administration approval for the management of novo, calcified, stenotic coronary arteries before stent placement.2,5 This technical video presents an illustrative case of a patient with symptomatic severely calcified carotid plaque with previous neck radiation precluding endarterectomy, treated with off-label use of balloon lithotripsy plus stent.6 The patient consented to the procedure....